[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 8, 1975

The Patient Package Insert

Author Affiliations

Tulane University Medical Center New Orleans

JAMA. 1975;233(10):1089. doi:10.1001/jama.1975.03260100059022

The Food and Drug Administration (FDA), as the government regulatory agency responsible for labeling prescription drugs for safe and effective use, has recently issued a patient package insert (PPI) which accompanies each package of prescribed oral contraceptives. Physicians need to be made aware that the FDA is proceeding to develop PPI's for many other prescription drugs. Some categories of drugs such as anticancer agents may not be required to have a PPI, but it is likely that PPIs will appear soon for the antihypertensives, digitalis, minor tranquilizers, and for other categories. The FDA is responding to pressure from legislative and consumer groups who are demanding that patients have "a right to know" more about medication doctors prescribe. The assumption is made that physicians are doing an inadequate job of instructing patients about possible adverse drug effects. In some hospitals, the clinical pharmacist is assuming more and more of a role